An overview of bacterial efflux pumps and computational approaches to study efflux pump inhibitors

Future Medicinal Chemistry

Volumn 8, Issue 2, 2016, Pages 195-210

  Jamshidi, Shirin ^a   Sutton, J Mark ^b   Rahman, Khondaker M ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b PUBLIC HEALTH ENGLAND   (United Kingdom)

Author keywords

antimicrobial resistance; bacterial pathogenicity; computational approaches; efflux pump inhibitor; molecular dynamics; multidrug efflux pump simulation; tripartite assembly

Indexed keywords

ANTIBIOTIC AGENT; BACTERIAL PROTEIN; MEMBRANE FUSION PROTEIN; MULTIDRUG EFFLUX PUMP INHIBITOR; MULTIPLE DRUG RESISTANCE EFFLUX PUMP; TRIPARTITE MULTIDRUG EFFLUX PUMP; UNCLASSIFIED DRUG; ANTIINFECTIVE AGENT; CARRIER PROTEIN; PYRIMIDINE; PYRIMIDINE DERIVATIVE;

ANTIBIOTIC RESISTANCE; BACTERIAL VIRULENCE; COMPUTER SIMULATION; CONFORMATIONAL TRANSITION; INNER MEMBRANE; MOLECULAR DYNAMICS; MULTIDRUG RESISTANCE; NONHUMAN; OUTER MEMBRANE; PRIORITY JOURNAL; REVIEW; BACTERIUM; CHEMISTRY; CLASSIFICATION; DRUG EFFECTS; METABOLISM; TRANSPORT AT THE CELLULAR LEVEL;

ANTI-BACTERIAL AGENTS; BACTERIA; BACTERIAL PROTEINS; BIOLOGICAL TRANSPORT; DRUG RESISTANCE, MULTIPLE, BACTERIAL; MEMBRANE TRANSPORT PROTEINS; MOLECULAR DYNAMICS SIMULATION; PYRIMIDINES;

EID: 84958043218     PISSN: 17568919     EISSN: 17568927     Source Type: Journal    
DOI: 10.4155/fmc.15.173     Document Type: Review

References (102)

1. Wong K, Ma J, Rothnie A, Biggin PC, Kerr ID. Towards understanDing promiscuity in multidrug efflux pumps. Trends Biochem. Sci. 39(1), 8-16 (2014).
2. Du D, van Veen HW, Luisi BF. Assembly and operation of bacterial tripartite multidrug efflux pumps. Trends Microbiol. 23(5), 311-319 (2015).
3. Wilson DN. Ribosome-targeting antibiotics and mechanisms of bacterial resistance. Nat. Rev. Microbiol. 12(1), 35-48 (2014).
4. Piddock LJ. Multidrug-resistance efflux pumps-not just for resistance. Nat. Rev. Microbiol. 4(8), 629-636 (2006).
5. Putman M, van Veen HW, Konings WN. Molecular properties of bacterial multidrug transporters. Microbiol. Mol. Biol. Rev. 64(4), 672-693 (2000).
6. Saier MH Jr, Tran CV, Barabote RD. TCDB: the Transporter Classification Database for membrane transport protein analyses and information. Nucleic Acids Res. 34, D181-D186 (2006).
7. Dawson RJ, Locher KP. Structure of a bacterial multidrug ABC transporter. Nature 443(7108), 180-185 (2006).
8. He X, Szewczyk P, Karyakin A et al. Structure of a cationbound multidrug and toxic compound extrusion transporter. Nature 467(7318), 991-994 (2010).
9. Yin Y, He X, Szewczyk P, Nguyen T, Chang G. Structure of the multidrug transporter EmrD from Escherichia coli. Science 312(5774), 741-744 (2006).
10. Murakami S, Nakashima R, Yamashita E, Matsumoto T, Yamaguchi A. Crystal structures of a multidrug transporter reveal a functionally rotating mechanism. Nature 443(7108), 173-179 (2006).
11. Drew D, Klepsch MM, Newstead S et al. The structure of the efflux pump AcrB in complex with bile acid. Mol. Membr. Biol. 25(8), 677-682 (2008).
12. Sun J, Deng Z, Yan A. Bacterial multidrug efflux pumps: mechanisms, physiology and pharmacological exploitations. Biochem. Biophys. Res. Commun. 453(2), 254-267 (2014).
13. Roberts MC. Tetracycline resistance determinants: mechanisms of action, regulation of expression, genetic mobility, and distribution. FEMS Microbiol. Rev. 19(1), 1-24 (1996).
14. Speer BS, Shoemaker NB, Salyers AA. Bacterial resistance to tetracycline: mechanisms, transfer, and clinical significance. Clin. Microbiol. Rev. 5(4), 387-399 (1992).
15. Davidson AL, Chen J. ATP-binDing cassette transporters in bacteria. Annu. Rev. Biochem. 73 241-268 (2004).
16. Rees DC, Johnson E, Lewinson O. ABC transporters: the power to change. Nat. Rev. Mol. Cell Biol. 10(3), 218-227 (2009).
17. Borges-Walmsley MI, McKeegan KS, Walmsley AR. Structure and function of efflux pumps that confer resistance to drugs. Biochem. J. 376(Pt 2), 313-338 (2003).
18. Omote H, Hiasa M, Matsumoto T, Otsuka M, Moriyama Y. The MATE proteins as fundamental transporters of metabolic and xenobiotic organic cations. Trends Pharm. Sci. 27(11), 587-593 (2006).
19. Pao SS, Paulsen IT, Saier MH. Major facilitator superfamily. Microbiol. Mol. Biol. Rev. 62(1), 1-34 (1998).
20. Paulsen IT, Skurray RA, Tam R et al. The SMR family: a novel family of multidrug efflux proteins involved with the efflux of lipophilic drugs. Mol. Microbiol. 19(6), 1167-1175 (1996).
21. Magnet S, Courvalin P, Lambert T. Resistance-nodulationcell division-type efflux pump involved in aminoglycoside resistance in Acinetobacter baumannii strain BM4454. Antimicrob. Agents Chemother. 45(12), 3375-3380 (2001).
22. Du D, Wang Z, James NR et al. Structure of the AcrABTolC multidrug efflux pump. Nature 509(7501), 512-515 (2014).
23. Ruiz N, Kahne D, Silhavy TJ. Transport of lipopolysaccharide across the cell envelope: the long road of discovery. Nat. Rev. Microbiol. 7(9), 677-683 (2009).
24. Silhavy TJ, Kahne D, Walker S. The bacterial cell envelope. Cold Spring Harb. Perspect. Biol. 2(5), a000414 (2010).
25. Koronakis V, Sharff A, Koronakis E, Luisi B, Hughes C. Crystal structure of the bacterial membrane protein TolC central to multidrug efflux and protein export. Nature 405(6789), 914-919 (2000).
26. Andersen C, Koronakis E, Hughes C, Koronakis V. An aspartate ring at the TolC tunnel entrance determines ion selectivity and presents a target for blocking by large cations. Mol. Microbiol. 44(5), 1131-1139 (2002).
27. Su CC, Radhakrishnan A, Kumar N et al. Crystal structure of the Campylobacter jejuni CmeC outer membrane channel. Protein Sci. 23(7), 954-961 (2014).
28. Nikaido H, Takatsuka Y. Mechanisms of RND multidrug efflux pumps. Biochim. Biophys. Acta 1794(5), 769-781 (2009).
29. Mikolosko J, Bobyk K, Zgurskaya HI, Ghosh P. Conformational flexibility in the multidrug efflux system protein AcrA. Structure 14(3), 577-587 (2006).
30. Akama H, Matsuura T, Kashiwagi S et al. Crystal structure of the membrane fusion protein, MexA, of the multidrug transporter in Pseudomonas aeruginosa. J. Biol. Chem. 279(25), 25939-25942 (2004).
31. Higgins MK, Bokma E, Koronakis E, Hughes C, Koronakis V. Structure of the periplasmic component of a bacterial drug efflux pump. Proc. Natl Acad. Sci. USA 101(27), 9994-9999 (2004).
32. Hinchliffe P, Greene NP, Paterson NG, Crow A, Hughes C, Koronakis V. Structure of the periplasmic adaptor protein from a major facilitator superfamily (MFS) multidrug efflux pump. FEBS Lett. 588(17), 3147-3153 (2014).
33. Greene NP, Hinchliffe P, Crow A, Ababou A, Hughes C, Koronakis V. Structure of an atypical periplasmic adaptor from a multidrug efflux pump of the spirochete Borrelia burgdorferi. FEBS Lett. 587(18), 2984-2988 (2013).
34. Nikaido H, Pages JM. Broad-specificity efflux pumps and their role in multidrug resistance of Gram-negative bacteria. FEMS Microbiol. Rev. 36(2), 340-363 (2012).
35. Bokma E, Koronakis E, Lobedanz S, Hughes C, Koronakis V. Directed evolution of a bacterial efflux pump: adaptation of the E. coli TolC exit duct to the Pseudomonas MexAB translocase. FEBS Lett. 580(22), 5339-5343 (2006).
36. Vediyappan G, Borisova T, Fralick JA. Isolation and characterization of VceC gain-of-function mutants that can function with the AcrAB multiple-drug-resistant efflux pump of Escherichia coli. J. Bacteriol. 188(11), 3757-3762 (2006).
37. Tsukagoshi N, Aono R. Entry into and release of solvents by Escherichia coli in an organic-aqueous two-liquid-phase system and substrate specificity of the AcrAB-TolC solventextruDing pump. J. Bacteriol. 182(17), 4803-4810 (2000).
38. Weeks JW, Bavro VN, Misra R. Genetic assessment of the role of AcrB beta-hairpins in the assembly of the TolCAcrAB multidrug efflux pump of Escherichia coli. Mol. Microbiol. 91(5), 965-975 (2014).
39. Murakami S, Nakashima R, Yamashita E, Yamaguchi A. Crystal structure of bacterial multidrug efflux transporter AcrB. Nature 419(6907), 587-593 (2002).
40. Symmons MF, Bokma E, Koronakis E, Hughes C, Koronakis V. The assembled structure of a complete tripartite bacterial multidrug efflux pump. Proc. Natl Acad. Sci. USA 106(17), 7173-7178 (2009).
41. Tamura N, Murakami S, Oyama Y, Ishiguro M, Yamaguchi A. Direct interaction of multidrug efflux transporter AcrB and outer membrane channel TolC detected via site-directed disulfide cross-linking. Biochemistry 44(33), 11115-11121 (2005).
42. Lobedanz S, Bokma E, Symmons MF, Koronakis E, Hughes C, Koronakis V. A periplasmic coiled-coil interface underlying TolC recruitment and the assembly of bacterial drug efflux pumps. Proc. Natl Acad. Sci. USA 104(11), 4612-4617 (2007).
43. Fernandez-Recio J, Walas F, Federici L et al. A model of a transmembrane drug-efflux pump from Gram-negative bacteria. FEBS Lett. 578(1-2), 5-9 (2004).
44. Trepout S, Taveau JC, Benabdelhak H et al. Structure of reconstituted bacterial membrane efflux pump by cryoelectron tomography. Biochim. Biophys. Acta 1798(10), 1953-1960 (2010).
45. Zgurskaya HI, Nikaido H. Cross-linked complex between oligomeric periplasmic lipoprotein AcrA and the innermembrane-associated multidrug efflux pump AcrB from Escherichia coli. J. Bacteriol. 182(15), 4264-4267 (2000).
46. Thanabalu T, Koronakis E, Hughes C, Koronakis V. Substrate-induced assembly of a contiguous channel for protein export from E.coli: reversible bridging of an innermembrane translocase to an outer membrane exit pore. EMBO J. 17(22), 6487-6496 (1998).
47. Misra R, Bavro VN. Assembly and transport mechanism of tripartite drug efflux systems. Biochim. Biophys. Acta 1794(5), 817-825 (2009).
48. Mima T, Joshi S, Gomez-Escalada M, Schweizer HP. Identification and characterization of TriABC-OpmH, a triclosan efflux pump of Pseudomonas aeruginosa requiring two membrane fusion proteins. J. Bacteriol. 189(21), 7600-7609 (2007).
49. Janganan TK, Bavro VN, Zhang L, Matak-Vinkovic D, Barrera NP, Venien-Bryan C et al. Evidence for the assembly of a bacterial tripartite multidrug pump with a stoichiometry of 3:6:3. J. Biol. Chem. 286(30), 26900-26912 (2011).
50. Kim JS, Jeong H, Song S et al. Structure of the tripartite multidrug efflux pump AcrAB-TolC suggests an alternative assembly mode. Mol. Cells 38(2), 180-186 (2015).
51. Huang YW, Hu RM, Chu FY, Lin HR, Yang TC. Characterization of a major facilitator superfamily (MFS) tripartite efflux pump EmrCABsm from Stenotrophomonas maltophilia. J. Antimicrob. Chemother. 68(11), 2498-2505 (2013).
52. Tal N, Schuldiner S. A coordinated network of transporters with overlapping specificities provides a robust survival strategy. Proc. Natl Acad. Sci. USA 106(22), 9051-9056 (2009).
53. Eswaran J, Koronakis E, Higgins MK, Hughes C, Koronakis V. Three's company: component structures bring a closer view of tripartite drug efflux pumps. Curr. Opin. Struct. Biol. 14(6), 741-747 (2004).
54. Janganan TK, Zhang L, Bavro VN et al. Opening of the outer membrane protein channel in tripartite efflux pumps is induced by interaction with the membrane fusion partner. J. Biol. Chem. 286(7), 5484-5493 (2011).
55. Janganan TK, Bavro VN, Zhang L, Borges-Walmsley MI, Walmsley AR. Tripartite efflux pumps: energy is required for dissociation, but not assembly or opening of the outer membrane channel of the pump. Mol. Microbiol. 88(3), 590-602 (2013).
56. Costa TR, Felisberto-Rodrigues C, Meir A et al. Secretion systems in Gram-negative bacteria: structural and mechanistic insights. Nat. Rev. Microbiol. 13(6), 343-359 (2015).
57. Nakashima R, Sakurai K, Yamasaki S, Nishino K, Yamaguchi A. Structures of the multidrug exporter AcrB reveal a proximal multisite drug-binDing pocket. Nature 480(7378), 565-569 (2011).
58. Sennhauser G, Bukowska MA, Briand C, Grutter MG. Crystal structure of the multidrug exporter MexB from Pseudomonas aeruginosa. J. Mol. Biol. 389(1), 134-145 (2009).
59. Seeger MA, Schiefner A, Eicher T, Verrey F, Diederichs K, Pos KM. Structural asymmetry of AcrB trimer suggests a peristaltic pump mechanism. Science 313(5791), 1295-1298 (2006).
60. Eicher T, Cha HJ, Seeger MA et al. Transport of drugs by the multidrug transporter AcrB involves an access and a deep binDing pocket that are separated by a switch-loop. Proc. Natl Acad. Sci. USA 109(15), 5687-5692 (2012).
61. Vazquez-Laslop N, Zheleznova EE, Markham PN, Brennan RG, Neyfakh AA. Recognition of multiple drugs by a single protein: a trivial solution of an old paradox. Biochem. Soc. Trans. 28(4), 517-520 (2000).
62. Martin C, Berridge G, Higgins CF, Mistry P, Charlton P, Callaghan R. Communication between multiple drug binDing sites on P-glycoprotein. Mol. Pharmacol. 58(3), 624-632 (2000).
63. Kobayashi N, Tamura N, van Veen HW, Yamaguchi A, Murakami S. Lactam selectivity of multidrug transporters AcrB and AcrD resides in the proximal binDing pocket. J. Biol. Chem. 289(15), 10680-10690 (2014).
64. Nakashima R, Sakurai K, Yamasaki S et al. Structural basis for the inhibition of bacterial multidrug exporters. Nature 500(7460), 102-106 (2013).
65. Vargiu AV, Nikaido H. Multidrug binDing properties of the AcrB efflux pump characterized by molecular dynamics simulations. Proc. Natl Acad. Sci. USA 109(50), 20637-20642 (2012).
66. Seeger MA, von Ballmoos C, Verrey F, Pos KM. Crucial role of Asp408 in the proton translocation pathway of multidrug transporter AcrB: evidence from site-directed mutagenesis and carbodiimide labeling. Biochemistry 48(25), 5801-5812 (2009).
67. Yao XQ, Kenzaki H, Murakami S, Takada S. Drug export and allosteric coupling in a multidrug transporter revealed by molecular simulations. Nat. Commun. 1 117 (2010).
68. Yao XQ, Kimura N, Murakami S, Takada S. Drug uptake pathways of multidrug transporter AcrB studied by molecular simulations and site-directed mutagenesis experiments. J. Am. Chem. Soc. 135(20), 7474-7485 (2013).
69. Ferreira RJ, Ferreira M-JU, dos Santos DJVA. Insights on P-glycoprotein's efflux mechanism obtained by molecular dynamics simulations. J. Chem. Theory Comput. 8(6), 1853-1864 (2012).
70. Song J, Ji C, Zhang JZ. Insights on Na(+) binDing and conformational dynamics in multidrug and toxic compound extrusion transporter NorM. Proteins 82(2), 240-249 (2014).
71. Vanni S, Campomanes P, Marcia M, Rothlisberger U. Ion binDing and internal hydration in the multidrug resistance secondary active transporter NorM investigated by molecular dynamics simulations. Biochemistry 51(6), 1281-1287 (2012).
72. Vaccaro L, Koronakis V, Sansom MS. Flexibility in a drug transport accessory protein: molecular dynamics simulations of MexA. Biophys. J. 91(2), 558-564 (2006).
73. Vaccaro L, Scott KA, Sansom MS. Gating at both ends and breathing in the middle: conformational dynamics of TolC. Biophys. J. 95(12), 5681-5691 (2008).
74. Yamane T, Murakami S, Ikeguchi M. Functional rotation induced by alternating protonation states in the multidrug transporter AcrB: all-atom molecular dynamics simulations. Biochemistry 52(43), 7648-7658 (2013).
75. Schulz R, Vargiu AV, Collu F, Kleinekathofer U, Ruggerone P. Functional rotation of the transporter AcrB: insights into drug extrusion from simulations. PLoS Comput. Biol. 6(6), e1000806 (2010).
76. Vargiu AV, Collu F, Schulz R et al. Effect of the F610A mutation on substrate extrusion in the AcrB transporter: explanation and rationale by molecular dynamics simulations. J. Am. Chem. Soc. 133(28), 10704-10707 (2011).
77. Pages JM, Amaral L, Fanning S. An original deal for new molecule: reversal of efflux pump activity, a rational strategy to combat Gram-negative resistant bacteria. Curr. Med. Chem. 18(19), 2969-2980 (2011).
78. Tanaka Y, Hipolito CJ, Maturana AD et al. Structural basis for the drug extrusion mechanism by a MATE multidrug transporter. Nature 496(7444), 247-251 (2013).
79. Lindahl E, Sansom MS. Membrane proteins: molecular dynamics simulations. Curr. Opin. Struct. Biol. 18(4), 425-431 (2008).
80. White DG, Goldman JD, Demple B, Levy SB. Role of the acrAB locus in organic solvent tolerance mediated by expression of marA, soxS, or robA in Escherichia coli. J. Bacteriol. 179(19), 6122-6126 (1997).
81. Yu EW, Aires JR, McDermott G, Nikaido H. A periplasmic drug-binDing site of the AcrB multidrug efflux pump: a crystallographic and site-directed mutagenesis study. J. Bacteriol. 187(19), 6804-6815 (2005).
82. Husain F, Nikaido H. Substrate path in the AcrB multidrug efflux pump of Escherichia coli. Mol. Microbiol. 78(2), 320-330 (2010).
83. Van Bambeke F, Pages JM, Lee VJ. Inhibitors of bacterial efflux pumps as adjuvants in antibiotic treatments and diagnostic tools for detection of resistance by efflux. Recent Pat. Antiinfect. Drug Discov. 1(2), 157-175 (2006).
84. Zechini B, Versace I. Inhibitors of multidrug resistant efflux systems in bacteria. Recent. Pat. Antiinfect. Drug. Discov. 4(1), 37-50 (2009).
85. Vargiu AV, Ruggerone P, Opperman TJ, Nguyen ST, Nikaido H. Molecular mechanism of MBX2319 inhibition of Escherichia coli AcrB multidrug efflux pump and comparison with other inhibitors. Antimicrob. Agents. Chemother. 58(10), 6224-6234 (2014).
86. Kourtesi C, Ball AR, Huang YY et al. Microbial efflux systems and inhibitors: approaches to drug discovery and the challenge of clinical implementation. Open. Microbiol. J. 7 34-52 (2013).
87. Tegos GP, Haynes M, Strouse JJ et al. Microbial efflux pump inhibition: tactics and strategies. Curr. Pharm. Des. 17(13), 1291-1302 (2011).
88. Mahamoud A, Chevalier J, Alibert-Franco S, Kern WV, Pages JM. Antibiotic efflux pumps in Gram-negative bacteria: the inhibitor response strategy. J. Antimicrob. Chemother. 59(6), 1223-1229 (2007).
89. Bush K, Courvalin P, Dantas G et al. Tackling antibiotic resistance. Nat. Rev. Microbiol. 9(12), 894-896 (2011).
90. Lomovskaya O, Bostian KA. Practical applications and feasibility of efflux pump inhibitors in the clinic-a vision for applied use. Biochem. Pharmacol. 71(7), 910-918 (2006).
91. Piddock LJ, Garvey MI, Rahman MM, Gibbons S. Natural and synthetic compounds such as trimethoprim behave as inhibitors of efflux in Gram-negative bacteria. J. Antimicrob. Chemother. 65(6), 1215-1223 (2010).
92. Stavri M, Piddock LJ, Gibbons S. Bacterial efflux pump inhibitors from natural sources. J. Antimicrob. Chemother. 59(6), 1247-1260 (2007).
93. Lu W, Zhong M, Wei Y. FolDing of AcrB subunit precedes trimerization. J. Mol. Biol. 411(1), 264-274 (2011).
94. Takatsuka Y, Chen C, Nikaido H. Mechanism of recognition of compounds of diverse structures by the multidrug efflux pump AcrB of Escherichia coli. Proc. Natl Acad. Sci. USA 107(15), 6559-6565 (2010).
95. Collu F, Vargiu AV, Dreier J, Cascella M, Ruggerone P. Recognition of imipenem and meropenem by the RNDtransporter MexB studied by computer simulations. J. Am. Chem. Soc. 134(46), 19146-19158 (2012).
96. Lomovskaya O, Watkins W. Inhibition of efflux pumps as a novel approach to combat drug resistance in bacteria. J. Mol. Microbiol. Biotechnol. 3(2), 225-236 (2001).
97. Askoura M, Mottawea W, Abujamel T, Taher I. Efflux pump inhibitors (EPIs) as new antimicrobial agents against Pseudomonas aeruginosa. Libyan J. Med. 6 (2011).
98. Nakayama K, Ishida Y, Ohtsuka M et al. MexAB-OprMspecific efflux pump inhibitors in Pseudomonas aeruginosa. Part 1: discovery and early strategies for lead optimization. Bioorg. Med. Chem. Lett. 13(23), 4201-4204 (2003).
99. Yoshida K, Nakayama K, Ohtsuka M et al. MexAB-OprM specific efflux pump inhibitors in Pseudomonas aeruginosa. Part 7: highly soluble and in vivo active quaternary ammonium analogue D13-9001, a potential preclinical candidate. Bioorg. Med. Chem. 15(22), 7087-7097 (2007).
100. Matsumoto Y, Hayama K, Sakakihara S et al. Evaluation of multidrug efflux pump inhibitors by a new method using microfluidic channels. PLoS ONE 6(4), e18547 (2011).
101. Opperman TJ, Nguyen ST. Recent advances toward a molecular mechanism of efflux pump inhibition. Front. Microbiol. 6, 421 (2015).
102. Feng Z, Hou T, Li Y. Unidirectional peristaltic movement in multisite drug binDing pockets of AcrB from molecular dynamics simulations. Mol. Biosyst. 8(10), 2699-2709 (2012).